Filing Details

Accession Number:
0001209191-19-057753
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-22 13:29:33
Reporting Period:
2019-11-20
Accepted Time:
2019-11-22 13:29:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1668243 Urogen Pharma Ltd. URGN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1585839 P. Peter Pfreundschuh C/O Urogen Pharma Ltd.
499 Park Avenue
New York City NY 10022
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-11-20 1,042 $0.00 3,793 No 4 M Direct
Ordinary Shares Disposition 2019-11-20 354 $28.41 3,439 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Units Disposition 2019-11-20 1,042 $0.00 1,042 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,291 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
  2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  3. The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.